Close

Alexion Pharmaceuticals (ALXN) Tops Q4 EPS by 7c; Issues FY12 EPS, Revs Outlook

February 9, 2012 6:34 AM EST
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q4 EPS of $0.41, $0.07 better than the analyst estimate of $0.34. Revenue for the quarter came in at $227.6 million versus the consensus estimate of $220.75 million.

Alexion Pharmaceuticals, Inc. sees FY2012 EPS of $1.60-$1.70, versus the consensus of $1.67. Alexion Pharmaceuticals, Inc. sees FY2012 revenue of $1.04-$1.07 billion, versus the consensus of $1.04 billion.

For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings